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We established two Epstein–Barr virus (EBV)-infected NKL sublines, which acquired stress resistant phenotype against DNA damage
and starvation compared with EBV-negative NKL. EBV-rendered doxorubicin resistance at least partially through NF-kB activation
and the resultant sustenance of antiapoptotic proteins including Bcl-XL and FLIPL/S.
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Natural killer (NK)-cell malignancies including nasal-type NK-cell
lymphoma and aggressive NK-cell leukaemia have been recently
recognised as new disease entities, which frequently arise in east
Asia and central America and present poor prognosis (Oshimi,
2007). These diseases are closely associated with Epstein–Barr
virus (EBV) infection (Kawa-Ha et al, 1989; Kaneko et al, 1995;
Oshimi, 2007). EBV genome was detected in approximately 98% of
nasal-type NK-cell lymphoma cases and 83% of aggressive NK-cell
leukaemia cases in Japan (Oshimi et al, 2002). The presence of
monoclonal EBV in neoplastic NK cells indicates that EBV
infection occurs prior to the clonal expansion.
EBV immortalises B cells in vitro.I nt h i ss i t u a t i o n ,E B Ve x p r e s s e s
several latent gene products including six EBV-determined nuclear
antigens, three latent membrane proteins, and two EBV-encoded
RNAs (EBERs) (Young and Rickinson, 2004). Although these EBV-
derived molecules function as transactivators and signal transducers
in the infected cells, most of these molecules except for EBNA1,
EBERs and occasional LMP1 are not expressed in nasal-type NK-cell
lymphoma (Xu et al, 2001). EBNA1, EBERs and LMP1 also contribute
to cellular transformation by affecting cellular gene expression and
protein stability (Nambo and Takada, 2002; Masucci, 2004; Young
and Rickinson, 2004; Samanta et al,2 0 0 6 ) .U n t i ln o w ,i th a sn o t
sufficiently elucidated the pathogenetic role of EBV in NK-cell
malignancies. Recently, we have shown that EBV directly infects
human NK cells in vitro (Isobe et al, 2004). In vitro EBV infection of
NK cells enabled us to establish two EBV-carrying NK-cell sublines
and to evaluate their phenotypic changes.
MATERIALS AND METHODS
Establishment of EBV-infected NKL sublines
Cell-culture condition and infection procedure were described
earlier (Isobe et al, 2004). We used EBV-negative NK-cell leukaemia
cell line, NKL as an EBV target cell (Robertson et al, 1996). NKL was
maintained in Iscove’s modified Dulbecco’s medium (Invitrogen,
Carlsbad, CA, USA) containing 100Uml
1 human interleukin (IL)-2
(a gift from Shionogi, Osaka, Japan). We previously confirmed that
this cell line had no mutations in exon 5-to-8 of TP53 gene (Sakajiri
et al, 2001). Akata (EBV-positive) and BJAB (EBV-negative) were
used as an EBV-producing cell and an EBV target control,
respectively. Akata is infected with recombinant EBV strain
containing neomycin-resistant gene (Yoshiyama et al,1 9 9 5 ) .A f t e r
selection with medium containing 700mgml
1 of G418 (Invitrogen),
EBV-infected clones were maintained for more than four years using
G418-free medium. BJAB was obtained from Fujisaki Cell Center,
Hayashibara biochemical laboratories Inc. (Okayama, Japan).
Southern blot analysis, western blot analysis, and flow
cytometry
Southern blot analysis was performed using EBV 1.9kb XhoI
probe and detected with CSPD detection system (Roche Diagnostics,
Basel, Switzerland). Western blot analysis was performed using
the following antibodies: anti-EBNA1 (Advanced Biotechnologies,
Columbia, MD, USA); anti-EBNA2; anti-LMP1; anti-ZEBRA, (Dako,
Glostrup, Denmark); anti-early antigen diffuse (EA-D), (Chemicon,
Temecula, CA, USA); anti-Bcl-2 (Dako); anti-Bcl-XL; anti-Mcl-1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-Bax (Cell
Signaling Technology, Danvers, MA, USA); anti-FLIP (Alexis,
Lausen, Switzerland); anti-FLIPg/d (Sigma-Aldrich, Stockholm,
Sweden); anti-Hsp 90 (Nventa, San Diego, CA, USA); anti-p53
(Santa Cruz); anti-phosphorylated p53 (Cell Signaling Technology);
and anti-b actin antibody (Sigma-Aldrich). Antibody signals were
enhanced and detected with ECL (Amersham International plc,
Buckinghamshire) or Western Blue (Promega, Madison, WI, USA).
Cell-surface P-glycoprotein (P-gp) was analysed by flow cytometry
using anti-P-gp antibody, MRK16 (Kyowa Medex, Tokyo, Japan).
Cell viability and apoptosis assay
Viable and dead cell numbers were determined by trypan-blue dye
exclusion. Each cell suspension (410
5ml
1) was treated with
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Figure 1 (A) NKL and BJAB were infected with Akata-derived EBV. Southern blot analysis detected monoclonal EBV genome in EBV-infected NKL cells.
The blotting signal for clone 2 (lane 4) is weaker than those of established EBV-infected NKL sublines named TL1 (lane 5) and TL2 (lane 6), suggesting that
clone 2 should contain less copy number of EBV. EBV-infected BJAB appears to consist of two clones (lane 2). (B) TL1 (lane 5) and TL2 (lane 6) express
EBNA1 and LMP1, but lack EBNA2 and lytic marker proteins, ZEBRA and EA-D. TPA-treated Akata (lane 1) and EBV-infected BJAB (lane 2) are positive
controls of lytic and latent phases, respectively. (C) Time courses of cell count for NKL, TL1, and TL2 at steady state. TL1 and TL2 showed no growth
advantage compared with NKL. Alive (trypan-blue negative)- and dead (trypan-blue positive)-cell counts are shown in gray- and black-bars, respectively.
(D) Time courses of cell count for NKL, TL1, and TL2 after treatment with 150nM of doxorubicin (DXR). After 48h, approximately 60% of NKL cells were
dead, whereas above 85% of TL1 and TL2 cells survived. (E) Change in cell morphology after 48h of treatment with DXR in three lines (Wright–Giemsa
stain1000). Although both TL1 and TL2 cells had no apparent change in their cell morphology, about half of NKL cells underwent apoptosis (arrowheads).
(F) A cell viability assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide after 48h of treatment with 4-hydroxycyclophosphamide, DXR,
vincristine, and BMS-345541, TL1 and TL2 showed resistance to DXR and VCR treatment compared with NKL. (G) Flow cytometric terminal
deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay after treatment with 150nM of DXR or serum depletion (from 10 to 0.1% of
fetal bovine serum). Although about half of NKL cells underwent apoptosis after each treatment, essentially no apoptotic populations were detected in TL1
and TL2. Open arrowheads show TUNEL-positive populations. (H) 7-amino actinomycin D rejection and annexin V-binding assay after treatment with DXR
or serum depletion. About half of NKL cells became positive for annexin V after each treatment. In contrast, approximately 90% of TL1 and TL2 cells were
negative for annexin V after each treatment.
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rubicin (DXR), vincristine (VCR) (Sigma-Aldrich), and I-kB kinase
inhibitor BMS-345541 (Merck KGaA, Darmstadt, Germany). We
assessed the cell viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Promega). The viabi-
lity was calculated as percent absorbance of formazan products,
that is, (OD570DXR-treated/OD570control)100%. We also
evaluated the cell death process by FITC-conjugated annexin
V-binding and 7-amino actinomycin D (AAD)-rejection assays
(Beckman Coulter, Fullerton, CA, USA). DNA nick ends in
apoptotic cells were labelled with fluorescein isothiocyanate
(FITC)-conjugated dUTP using Mebstain Apoptosis Kit (Beckman
Coulter) and analysed by flow cytometry.
Nuclear factor-jB activity assay
DNA binding activity of nuclear factor (NF)-kB was evaluated
using an enzyme-linked immunosorbent assay method. Nuclear
extract (10mg) was isolated from DXR-treated and untreated cells
and assayed using NF-kB p65 Transcription Factor assay Kit
(Chemicon). Relative absorbance was calculated as follows:
OD450/OD650– OD450control/OD650control.
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Figure 1 Continued.
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sRESULTS
Establishment of EBV-carrying NKL sublines
We initially obtained three G418-resistant NKL subclones contain-
ing monoclonal EBV genome (Figure 1A). During the 4 years of
incubation, clone 2 stopped proliferation, and we finally estab-
lished two EBV-infected sublines named TL1 and TL2. Western
blot analysis showed expression of EBNA1 in all EBV-infected
subclones (Figure 1B). EBNA2 and lytic marker proteins, ZEBRA
and EA-D were absent in these clones. In addition, LMP1 was
detected in TL1 and TL2 but not in clone 2. LMP1 in TL1 and TL2
showed smaller sizes than that in EBV-infected BJAB (Figure 1B).
These truncated forms resemble lytic LMP1 detected in
TPA-treated Akata (Figure 1B). Because lytic marker proteins
were absent in both sublines, detection of the truncated forms
may represent rapid turnover of LMP1 in TL1 and TL2.
EBV infection of NKL showed no growth advantage but
rendered the infected cells resistant to doxorubicin-
induced apoptosis
NKL and EBV-infected TL1 and TL2 showed no difference in cell
growth at a steady state (Figure 1C). After treatment with 150nM of
DXR, both sublines remained more viable than NKL, that is,
although approximately 60% of NKL cells became positive for
trypan-blue dye exclusion assay after 48h, less than 14% of TL1
and TL2 cells were dead (Figure 1D). Indeed, about half of NKL
cells underwent apoptosis after the DXR treatment (Figure 1E). We
also evaluated possible difference of drug sensitivity among NKL,
TL1 and TL2 using 4-HC, DXR, VCR, and I-kB kinase inhibitor
BMS-345541. After 48h of treatment, MTT assay showed that TL1
and TL2 were more resistant to DXR than NKL (Figure 1F).
Although NKL itself was rather resistant to VCR compared with
BJAB, the sublines were a little more refractory to the agent. The
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Figure 2 (A) Western blot analysis showed essentially the same expression levels of Bcl-2, Bcl-XL, Mcl-1, Bax, FLIPL/S, and p53 among NKL, TL1 and TL2.
(B) Cell-surface P-glycoprotein was absent not only in NKL but also TL1 and TL2 by flow cytometry. Open histograms show negative control with isotype-
matched control antibody. (C) Alterations of antiapoptotic protein levels in NKL and two sublines after doxorubicin (DXR) treatment. Although NKL
declined expression levels of Bcl-2, Bcl-XL, and FLIPL/S after 24h of DXR treatment (left column), TL1 (middle column) and TL2 (right column) kept to
express these proteins, and showed rather increased expression levels of Bcl-XL and FLIPL/S.( D) NF-kB (p65 subunit) binding activity after DXR treatment.
Although the binding activity in NKL remained to be its basal level at 24h, those in TL1 and TL2 increased approximately five times after 12h and further
boosted at 24h. In contrast, NF-kB inhibitor BMS-345541 almost completely suppressed DXR-induced NF-kB activation in all three lines. Each experiment
was performed in triplicate. Each error bar represents s.d. (E) Alterations of antiapoptotic protein levels in NKL and two sublines after treatment with both
DXR and BMS-345541. In the presence of BMS-345541, treatment with DXR clearly decreased expression levels of Bcl-XL and FLIPL/S even in TL1 and TL2.
Expression level of Bcl-2 was decreased only in NKL. (F) 7-amino actinomycin D rejection and annexin V-binding assay after treatment with DMSO
(control), BMS-345541, DXR, and both BMS-345541 and DXR. Although approximately 5–7% of apoptotic populations were detected in TL1 and TL2
after treatment with 3mM of BMS-345541 and 150nM of DXR, respectively, those mixed treatments induced apoptosis in approximately 40% of populations
in TL1 and TL2.
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between NKL and its sublines. Flow cytometric terminal deoxy-
nucleotidyl transferase-mediated dUTP nick end-labelling assay
showed that treatment with 150nM of DXR or serum depletion
(10% to 0.1%) for 48h induced apoptosis in about half of NKL cells
but in only few TL1 and TL2 cells (Figure 1G). Annexin V-binding
and 7-AAD-rejection assays confirmed the loss of susceptibility to
DXR and serum depletion in TL-1 and TL-2 (Figure 1H). These
results showed that EBV rendered the infected NKL cells resistant
to various cell stresses like DNA damage and starvation.
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after EBV infection of NKL cells. Western blot analysis showed
essentially the same levels of Bcl-2, Bcl-XL, Mcl-1, Bax, p53 and
FLIPL/S among NKL, TL1 and TL2 (Figure 2A). Expression of
MDR1-encoded P-gp was absent in all these lines, which confirmed
that the resistance to DXR should be unrelated to drug pumping
(Figure 2B). Although no apparent difference was detected at the
steady state, treatment with 150nM of DXR for 24h reduced
expression levels of Bcl-2, Bcl-XL, and FLIPL/S specifically in NKL
(Figure 2C). The amounts of these proteins were constant or rather
increased in TL1 and TL2 after the same treatment. Protein levels
of Mcl-1 and Bax were unchanged in all three lines (Figure 2C).
Increased levels of p53 phosphorylation at serine-15 after DXR
treatment indicated preservation of normal p53 activity in all three
lines (Figure 2C). Because nuclear factor (NF)-kB is reported to
affect expression levels of Bcl-XL and FLIPL/S (Karin, 2006), we
examined possible involvement of NF-kB in the EBV-mediated
resistance to DXR. In spite of a transient increase at 12h, target
sequences-binding activity of NF-kB p65 clearly regressed after
24h of DXR treatment in NKL (Figure 2D). In contrast, although
the basal activities in TL1 and TL2 were rather suppressed, they
increased approximately five times as high as their basal levels
after 12h of DXR treatment, and were further boosted at 24h
(Figure 2D). However, NF-kB inhibitor BMS-345541 almost
completely suppressed DXR-induced NF-kB activation in all three
lines. In the presence of this inhibitor, treatment with DXR clearly
decreased expression levels of Bcl-XL and FLIPL/S and induced
massive apoptosis even in TL1 and TL2 (Figure 2E and F). It
should be noted that BMS-345541 rather decreased the apoptotic
cell percentage from approximately 60% to around 35% in DXR-
treated NKL. These experiments were repeated at least three times
with essentially the same results.
DISCUSSION
In this study, we established TL1 and TL2, which contain
monoclonal EBV genome and showed type II latency. Their
manner of infection corresponds to the clinical setting of NK-cell
malignancies (Xu et al, 2001). The intense signals in Southern blot
analysis suggested that TL1 and TL2 should contain greater copy
number of EBV genome than clone 2 (Figure 1A). Relatively high
copy number of EBV may contribute to successful maintenance of
TL1 and TL2 over 4 years. We previously detected truncated forms
of LMP1 at a later phase of latent infection (Isobe et al, 2004).
Although full-length LMP1 induces NF-kB activation, its truncated
form is reported to inhibit this effect (Erickson and Martin, 2000).
The canonical function of LMP1 seems to be limited and might not
fully contribute to establish the latent infection in both NKL
sublines. These truncated forms might explain the relatively low
basal NF-kB activity in TL1 and TL2 compared with NKL. Of
course, latent EBV infection may exert a supportive role for the
NF-kB pathway and might lessen its activity without altering basal
cell growth activity in both sublines.
At a steady state, TL1 and TL2 had no growth advantage and
showed essentially the same expression levels of several anti-
apoptotic proteins as NKL. However, these EBV-infected sublines
were apparently more resistant to DXR and serum depletion than
NKL. The results indicate that EBV infection conferred resistance
to various cell stresses like DNA damage and starvation in NKL.
Expression levels of Bcl-2, Bcl-XL and FLIPL/S decreased in NKL
but not in two sublines after DXR treatment. In the presence of
NF-kB inhibitor BMS-345541, both NKL and the EBV-infected
sublines were almost equally sensitive to DXR and failed to
maintain the expression levels of Bcl-XL and FLIPL/S after DXR
treatment. The results are completely in line with the previous
report that constitutively activated NF-kB has shown to maintain
high expression levels of Bcl-XL and FLIPL/S and confer resistance
to some anticancer drugs (Wang et al, 1999; Karin, 2006). EBV-
associated gene products like EBNA1 and LMP1 were reported to
modify the ubiquitin–proteasome activity and affect proteolysis of
various cellular proteins including NF-kB (Masucci, 2004). In
addition, EBERs appear to be involved in modulation of cellular
response and were reported to activate NF-kB-signalling pathway
(Nambo and Takada, 2002; Samanta et al, 2006). These observa-
tions strongly argue that the presence of EBV must render NKL
more resistant to lethal stress like DNA damage at least partially
through the NF-kB pathway.
During a series of experiments aimed to show the contribution
of NF-kB activity in stress resistance of TL1 and TL2, we found
that BMS-345541 reproducibly attenuated DXR-induced apoptosis
in NKL cells. Atypical activators of NF-kB including DXR have
been shown to convert p65 from a transcriptional activator into a
transcriptional repressor of antiapoptotic genes including Bcl-XL
and FLIPL/S (Campbell et al, 2004; Dutta et al, 2006). We believe
that DXR may induce apoptosis in NKL at least partially through
this atypical activation of NF-kB. Prolonged activation of NF-kB
during DXR treatment maintained high expression levels of Bcl-XL
and FLIPL/S in the EBV-infected sublines. Therefore, we suppose
that in the presence of some EBV-associated gene products, even
DXR treatment may preferentially elicit classical NF-kB activity
with an antiapoptotic feature rather than inducing the pro-
apoptotic situation and thus render the cell resistant to apop-
tosis. Abrogation of both positive and negative impacts of
NF-kB on apoptosis by BMS-345541 should bring about essentially
the same behaviour of NKL, TL1 and TL2 toward the DXR
treatment.
In conclusion, we report here in vitro establishment of two
EBV-infected NKL sublines, TL1 and TL2. Although the infected
sublines had no growth advantage compared with NKL, they
showed a resistant phenotype to stress-induced apoptosis at least
partially through the NF-kB activation and the resultant suste-
nance of Bcl-XL and FLIPL/S. We believe that this model suggests
the contribution of EBV in NK-cell tumorigenesis.
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